Sarepta Plunges Again After Europe Rejects Elevidys
Perhaps analysts at HC Wainwright & Co. were right about their 12-month zero-dollar price target for Sarepta Therapeutics. Following Sarepta's withdrawal of its Duchenne muscular dystrophy gene therapy drug from U.S. markets earlier this week, it …